Primary Sclerosing Cholangitis

2015 ◽  
Author(s):  
Udayakumar Navaneethan

Primary sclerosing cholangitis (PSC) is a chronic progressive cholestatic disease characterized by inflammation and fibrosis that may involve the entire biliary tree. The fibrosis causes diffuse narrowing of the intrahepatic and extrahepatic bile ducts, and the resulting biliary stasis leads to secondary biliary cirrhosis and associated complications. This review addresses PSC through its epidemiology, etiopathogenesis, diagnosis, differential diagnosis, management, complications, and prognosis. Figures show pouchoscopy, liver biopsy, and endoscopic retrograde cholangiopancreatography; direct peroral cholangioscopy visualization of cholangiocarcinoma; and algorithms depicting diagnosis of cholangiocarcinoma and screening for inflammatory bowel disease (IBD) in patients with PSC. Tables list characteristics of IBD in PSC, prevalence of antibodies in PSC, differential diagnosis of PSC, diagnostic approach in PSC, and risk of cancers in PSC. This review contains 6 highly rendered figures, 5 tables, and 91 references. 

2013 ◽  
Vol 2013 ◽  
pp. 1-5 ◽  
Author(s):  
Yinka K. Davies ◽  
Cynthia J. Tsay ◽  
Dario V. Caccamo ◽  
Kathleen M. Cox ◽  
Ricardo O. Castillo ◽  
...  

Primary sclerosing cholangitis (PSC) is a progressive, cholestatic disease of the liver that is marked by inflammation of the bile ducts and damage to the hepatic biliary tree. Approximately 60–70% of patients also have inflammatory bowel disease and progression of PSC can lead to ulcerative colitis and cirrhosis of the liver. Due to limited understanding of the etiology and mechanism of PSC, the only existing treatment option is orthotopic liver transplantation (OLT); however, recurrence of PSC, after OLT is estimated to be between 5% and 35%. We discuss the successful treatment of a pediatric patient, with recurrent PSC, after OLT with oral Vancomycin.


2010 ◽  
Vol 2010 ◽  
pp. 1-4
Author(s):  
Siu-Tong Law ◽  
Wai-Ki Lee ◽  
Michael Kin-Kong Li ◽  
Ka-Ho Lok

Primary sclerosing cholangitis is a rare cause of cholestasis caused by progressive inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts leading to multifocal ductal strictures. Herein, we report a case of primary sclerosing cholangitis and inflammatory bowel disease. The concomitant diagnosis of these two diseases is not typical. The management includes the treatment of inflammatory bowel disease and potential complications of primary sclerosing cholangitis, including dominant strictures of bile duct, portal hypertension, gallbladder diseases, cholangiocarcinoma, and colonoscopic surveillance.


Author(s):  
R.W. Chapman ◽  
K.D. Williamson

Case History—A 60 yr old woman, known to have long standing colitis, now presenting with abdominal pain and weight loss. Primary sclerosing cholangitis is a chronic cholestatic liver disease caused by diffuse inflammation and fibrosis that can involve the entire biliary tree. The cause is unknown, but presumed to be immune mediated, and there is a very close association with inflammatory bowel disease, particularly ulcerative colitis....


2020 ◽  
Vol 14 (Supplement_1) ◽  
pp. S633-S634
Author(s):  
M B Sanchez ◽  
M J Etchevers ◽  
J A De Paula ◽  
R Gonzalez Sueyro ◽  
P Daffra ◽  
...  

Abstract Background Inflammatory bowel diseases (IBD) and primary sclerosing cholangitis (PSC) are closely related. IBD-PSC has clinical characteristics that distinguish it from IBD without autoimmune liver disease (ALD). The association between autoimmune hepatitis (AH), overlapping syndrome (OS), primary biliary cirrhosis (PBC) and IBD is less known. Methods Clinical records of patients with IBD and PSC, AH, OS and PBC in a reference centre were reviewed retrospectively. Primary objective: to estimate the prevalence of ALD in patients with IBD. Secondary objectives: to establish the temporal gap between diagnosis of IBD and hepatopathy, severity of IBD, transplant requirement, displasia/colorectal carcinoma (CRC), and correlation between symptoms and endoscopic findings. All variables were compared according to liver disease. Results Of 1895 patients with IBD, 108 (5.7% [CI95% 4.7–6.8%]) had concomitant ALD, 78 PSC, 27 AH, 3 OS; no patient had PBC. 96.3% were associated with ulcerative colitis (UC). The prevalence of ALD in patients with UC was 7.6% (CI95% 6.3–9.2) and 1% (CI95% 0.3–2.5%) in patients with Crohn’s Disease. In patients with PSC, 56.4% were men, IBD diagnosis was previous than hepatopathy in 54.3% (median time 8.0 years), subsequent in 10% (7.9 years) and simultaneous, less than 1 year, in 35.7%. Conversely, in patients with AH, 55.6% were women, IBD was first diagnosed in 16% (median time 6.5 years), subsequent in 40% (5.3 years) and simultaneous in 44.0%. The median age at diagnosis was 32.5 (IQR 19.5–50.1) years for PSC and 13.1 (IQR 5.6–16.0) years for AH. Of 77 patients with available data, 97% had extensive colitis, without difference between PSC and AH. Patients with AH had more severe phenotype than PSC (Graphic 1). High grade dysplasia/CRC was detected in 5 patients (9.6%) all with PSC. Liver transplantation was required in 38.5% of PSC-UC patients and in 20% of AH-UC patients. Regarding endoscopic-clinical concordance, 52% of patients with moderate-severe endoscopic score were asymptomatic with similar behaviour in both hepatopathies. Conclusion PSC and AH were the most frequent ALD associated with IBD, mostly extensive UC. In contrast to PSC, AH tended to be diagnosed before intestinal disease and at an earlier age with higher biological and hospital admissions requirement. More than a half of our cohort had an important clinical-endoscopic dissociation, so we emphasise the relevance of the objective measurement of inflammation with colonoscopy in this particular group of patients


2012 ◽  
Vol 26 (5) ◽  
pp. 261-268 ◽  
Author(s):  
Natasha Chandok ◽  
Gideon M Hirschfield

Primary sclerosing cholangitis (PSC) is a chronic inflammatory cholangiopathy that results in fibrotic strictures and dilations of the intra- and extrahepatic bile ducts. PSC is uncommon, occurs predominantly in males and has a strong association with inflammatory bowel disease. While the pathogenesis of PSC has not been fully elucidated, emerging evidence supports roles for the innate and adaptive immune systems, and genome-wide analyses have identified several genetic associations. Using the best available evidence, the present review summarizes the current understanding of the diagnosis, pathogenesis and management of PSC. Despite its rarity, there is an urgent need for collaborative research efforts to advance therapeutic options for PSC beyond liver transplantation.


2020 ◽  
Vol 158 (6) ◽  
pp. S-732-S-733
Author(s):  
Camilla A. Martins ◽  
Ana Elisa R. Caon ◽  
Marilia G. Cruz ◽  
Luísa L. Barros ◽  
Alexandre Carlos ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document